William Blair acted as the exclusive financial advisor to International Chemical Investors Group (ICIG) in connection with its pending sale of its portfolio company, CordenPharma, to Astorg. The transaction was announced on May 2, 2022.
About the Companies
CordenPharma, the global pharmaceutical-service and manufacturing-platform of ICIG, is a full-service partner in the contract development and manufacturing of APIs, excipients, drug products, and associated packaging services. Through a growing network of cGMP facilities across Europe and the U.S., organized under five technology platforms: peptides, lipids and carbohydrates, injectables, highly potent oncology and small molecules, CordenPharma experts translate complex processes and projects at any stage of development into high-value products.
ICIG is a privately-owned industrial group with total sales of €3 billion. The company focuses on three main platforms: pharmaceuticals under the CordenPharma brand, fine chemicals under the WeylChem brand and chlorovinyls under the Vynova brand. Since its inception in 2004, ICIG has grown to operate more than 20 independent chemicals and pharmaceutical businesses, all of which have origins in major global chemical or pharmaceutical corporations. Today, ICIG companies employ approximately 5,685 employees and operate more than 25 manufacturing facilities in Europe and the United States.
Astorg is a European private equity firm with over €15 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe and the U.S., providing them with the strategic guidance, governance, and capital they need to achieve their growth plans. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business-services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan, and Luxembourg.
Learn more about our healthcare services investment banking expertise.